DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa. The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.
The study population will be recruited in two cohorts. The microbiological population of the wound will be evaluated to analyze the effect of the treatment. If the safety profile and treatment effect are going to be satisfactory, the recruitment will proceed with Cohort 2. In both cohorts, the Investigational Medicinal Product (IMP) or placebo (the randomization ratio will be 1:1) will be applied twice a day for two weeks or until the commencement of healing. Patients will receive the standard of care during the whole study duration. No concomitant treatment is planned during the treatment period. The Adverse Events will be recorded on basis of an open interview without soliciting questions, and clinical observation. In case of occurrence of an adverse event (AE) with moderate or severe intensity possibly related to IMP, the treatment will be stopped, and the AE will be followed up until resolution. Adverse Event descriptions, their severity (mild, moderate, or severe), duration and their perceived relationship to the study medication (probable, possible, unlikely, not related, and not sure) will be recorded. The mLUMT (modified Leg Ulcer Measurement Tool) total score and individual item scores change since the baseline visit will be recorded. Time from the start of the study treatment until the bacterial infection eradication - i. e. the swab sample is negative on S. aureus and/or P. aeruginosa will be recorded. Time from the start of the study treatment until the wound is closed/healed (as assessed by investigator) will be recorded.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
52
DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
St. Anne's University Hospital Brno
Brno, Czech Republic, Czechia
RECRUITINGPrimary endpoint - Cohort 1
The endpoint will be the frequency of all (local and systemic) reactions with suspected or confirmed relation to IMP.
Time frame: 10 weeks (the maximum duration)
Primary endpoint - pooled Cohorts 1 & 2
Time to commencement of healing.
Time frame: 10 weeks (the maximum duration)
Safety endpoints (assessed in pooled Cohorts 1 & 2)
The frequency of the following symptoms following the IMP application will be evaluated: local reactions, systemic reactions.
Time frame: 10 weeks (the maximum duration)
Microbiological endpoints (assessed in pooled Cohort 1 and Cohort 2)
Change of the microbiological profile of the wound assessed by swab.
Time frame: 2 weeks (the maximum duration)
Clinical efficacy endpoints
The mLUMT total score change since Baseline, time since the start of the study treatment until the bacterial infection eradication, time since the start of the study treatment until the granulation process in the wound has started, time since the start of the study treatment until the wound is closed as assessed by Investigator.
Time frame: 10 weeks (the maximum duration)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.